An official website of the United States government
Home
This neoplasm is not reportable.
Name
ICD-O-3 Morphology
Effective
2021 and later
Reportability
This neoplasm is not reportable
Primary Site(s)
C421
Primary site bone marrow (C421)
This hematopoietic disease is not reportable for the U.S.
Canada, refer to your specific province for reportability requirements.
This hematopoietic disease is not reportable for the U.S.
Canada, refer to your specific province for reportability requirements.
Abstractor Notes
IgM monoclonal gammopathy of undetermined significance (IgM MGUS) is part of the Plasma cell neoplasms and other diseases with paraproteins lineage table in the WHO 5th edition of Hematolymphoid Tumors. (See Appendix B in the Hematopoietic Manual, Table B17)
Neoplastic cells reside in the bone marrow.
Patients with IgM MGUS lack the signs and symptoms of an overt lymphoproliferative disorder of plasma cell neoplasm, and the paraprotein is typically discovered incidentally on serum protein electrophoresis.
Neoplastic cells reside in the bone marrow.
Patients with IgM MGUS lack the signs and symptoms of an overt lymphoproliferative disorder of plasma cell neoplasm, and the paraprotein is typically discovered incidentally on serum protein electrophoresis.
Definition
IgM monoclonal gammopathy of undetermined significance (MGUS) is defined by the presence of a serum monoclonal (M) protein of < 3 g/dL, < 10% bone marrow lymphoplasmacytic infiltration (clonal B cells and plasma cells together), and no evidence of anemia, constitutional symptoms, hyperviscosity, lymphadenopathy, or hepatosplenomegaly that can be attributed to the underlying lymphoproliferative disorder. (WHO 5th edition)
Genetics Data
This data item does not apply
Immunophenotyping
This data item does not apply
Transformations to
This data item does not apply
Corresponding ICD-10 Codes (Cause of Death codes only)
D47.2 Monoclonal gammopathy
Corresponding ICD-10-CM Codes (U.S. only)
D47.2 Monoclonal gammopathy (effective October 01, 2015)
Sources
WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. Lyon (France): International Agency for Research on Cancer; 2024. (WHO classification of tumours series, 5th ed.; vol. 11). https://publications.iarc.who.int/637.
Section: Plasma cell neoplasms and other diseases with paraproteins
Pages: Part B: 602
Section: Plasma cell neoplasms and other diseases with paraproteins
Pages: Part B: 602
International Classification of Diseases for Oncology, 3rd edition (including revisions). Geneva: World Health Organization, 2001, 2011, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
PDQ® Adult Treatment Editorial Board. PDQ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. Bethesda, MD: National Cancer Institute. Updated <03/28/2025>. Available at: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq. Accessed <03/30/2025>. [PMID: 26389362]
Section: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq
Section: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version
Pages: https://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq
